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Cancer Services Report
William J. La[fey
Regional Director,
Cancer Services

The Cancer Services Team vithin
the Metro Region of Aur,5fra
Health Care is most plised to
present this year’s an,n{ial report.
Within these pagçs’you will see
a compreheniness of care
made pos111e only through the
zlëdication and cooperation
of health professionals working
together to provide a better
patient care experience.

With a focus upon colorectal
cancer, one of the leading causes of death in the United
States, the articles contained in this report demonstrate
the intellectual, interdisciplinary
approach directed toward cancer
prevention, diagnosis and treatment.
Less readily apparent in a written
document, but equally important, is the
passion and desire for excellence shown
by all physicians and staff. Attendance
at tumor conferences, stereotactic
conferences, or treatment planning
sessions would impress the observer
with the fact that Aurora Health Care
has discovered a way to combine
advances in technology with compassion
and concern.

of psycho-oncology and genetics
counseling, gynecologic oncology
and coordination of patient care
throughout the region, Aurora
continues serving as a model for
personalized advanced cancer
diagnosis and treatment.
We hope you will enjoy reading this
report and discovering both the
intellect and compassion within our
system. It is a combination of which
we are proud and one which has a
single focus quality patient care.
—

As we continue to work together as a
region, our strategic planning process will allow us to
redefine cancer care across the continuum as our clinicians
and scientists combine their efforts towards prevention,
control, increased survival and improvements in quality of
life. With advances in technology such as acquisition of a
gamma knife, expansion of services, especially in the areas
3
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cancer committee
chairpersons’ reports
/1

I am honored and excited vb
be the new Chairman of7e
St. Luke’s Cancer Comyiittee.
I will have to admit IAvas a little
nervous and anxiois about
the appointme-i Dr. Marcia
:.,
Richarasiio has been the
—hirperson for the past 10 years,
St. Luke’s Medical Center has done an outstanding job with
Chairman’s Report the Cancer Committee. It will be
Jeffrey A. Derus, MD
a tough act to follow. All of us at
Chairman,
St. Luke’s Medical Center St. Luke’s and those on the Cancer
Committee wish to say “Thank
you for a job well done.” Her commitment to the Cancer
Committee and excellence has improved the lives of cancer
patients throughout our community.
Looking back on the activities of the Cancer Committee
during the past year, several exciting developments have
occurred. Dr. Jeffrey Knajdl, a psychiatrist, has helped
develop and is the Director of the new psychosocial
oncology program at St. Luke’s Medical Center and the
Vince Lombardi Cancer Clinics. The program’s mission is
to identify and treat psychosocial distress in cancer patients.
Already over 1,200 contacts with patients and family
members have been recorded at St. Luke’s Medical Center;
the Vince Lombardi Cancer Clinics and the Cancer
Counseling Center itself.
A new lymphedema program for upper and lower
extremities was implemented in November 199$ at St.
Luke’s Medical Center. The lymphedema program has been
expanded for the metro region and is being offered at West
Allis Memorial Hospital, Aurora Rehab Center in Slinger
and new programs are opening this year at Sinai Samaritan
Medical Center and the Aurora Rehab Center in Waukesha.

Lymphedema can be treated and
controlled allowing people to lead
more positive and productive lives.
In 199$, Marija Bjegovich-Weidman
resigned as the regional director of
cancer services. She will be greatly
missed. She was replaced by William
Laffey who comes to us from Boston,
Massachusetts. Mr. Laffey has over
20 years of health care field experience
and will be a great asset to the Cancer
Committee and Cancer Services.
Last year St. Luke’s Medical Center
was upgraded from a Commission on
Cancer “Community Cancer Program”
to a “Comprehensive Community
Cancer Program,” due to the fact that
we see over 750 cancer cases a year
(1,920 in 199$).
In January 199$, we had our first
regional cancer committee meeting,
which consisted of representatives
from West Allis Memorial Hospital,
Sinai Samaritan Medical Center, and
St. Luke’s Medical Center. To welcome
in the new millennium, the Regional
Cancer Committee is working on
teleconferencing of the tumor boards
in the Aurora Metro RegiontO
facilitate the discussion of interesting
cases and educatona1 topics relating
to oncology and the establishment of
Hartford 1emorial Hospital as an
accredited’ program as well.

/1
brain lesions. Gamma Knife applications include treating
primary malignant, metastatic or benign brain tumors and
arterial venous malformations and for such debilitating
conditions as trigeminal neuralgia. The Gamma Knife
radiosurgery precludes the need for open brain surgery or
hospitalization. These patients can be treated almost
exclusively in an outpatient setting. St. Luke’s decision to
purchase Wisconsin’s first Gamma Knife affirms its
commitment to developing cutting edge advances in
cancer programs and technology.

Community outreach activities have
taken place throughout the year and
can be found in the education
outreach activities in the annual
report. The Vince Lombardi Golf
Classic and Ball was a great success
last year, thanks to the generosity of
the volunteers and support from the
Vince Lomardi Clinic. The Vince
Lombardi Cancer Hotline served as a
“call to action” for a multimedia
campaign for cancer prevention and
early detection awareness. Phone
banks were held during the
evening news on WTMJ-4 and
promoted in statewide newspapers.
A cancer risk assessment
questionnaire was offered to
callers, which can provide risk
assessment for 19 primary
cancer sites.

d

--

Exciting new developments on the
horizon include the new St. Luke’s
South Shore Vince Lombardi
Cancer Clinic, which opened in
early 1999. Other sites opening
Vince Lombardi Cancer Clinics this
year include Elkhorn and West Bend.
In the fall of 1999, St. Luke’s Medical
Center established and opened the
first operarional Gamma Knife in
Wisconsin. Gamma Knife is a state
of the art, high technological tool
dedicated to perform radiosurgery on

1999
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Sinai Samaritan
Medical Center
Cancer Committee
Chairman’s Report
William L. Donegan, MD
FACS

Medical Center (SSMC)

The overall effort against
cancer can be enhanced yith
collaboration between irstitutions
as well as between disiplines.
This is accomplisd when each
institution c511?r(rates its own
strengtbsáiid at the same time
cdiiributes to a complete program
of cancer prevention, detection
and treatment. In 199$, progress
was made toward an integrated
cancer program between Aurora
institutions in the Milwaukee
metro area. Sinai Samaritan
was an active participant.

Initiation of a cancer network
began with the appointment of a
regional director for Cancer
Services, who effectively moved
the process forward. A regional
cancer committee met for the first
time. This meeting provided the
chairs of the cancer committee at
each hospital a means to share information and discuss
common goals and research objectives. A pilot project
was initiated to share tumor board programs and
educational presentations on cancer through innovative
teleconferencing. Lisa Robinson assumed the task of
standardizing the data collection systems in the region.
Under her guidance the cancer registries at each institution
are being melded into one information system. For the first
time, the cancer program annual report was published
jointly as a composite of information from each Aurora
metro institution. The report included cancer registry data
and educational contributions from each of our medical
centers, the in-depth site topic featured breast cancer, the

most frequent cancer we are called
upon to diagnose and treat.
Currently, SSMC’s cancer program is
approved independently as that of a
comprehensive community hospital
program. Ultimately the goal is to
seek Commission on Cancer approval
of Aurora hospitals as a cancer
program network.
Programs of service and education
marked the year at SSMC. The cancer
committee met on four occasions
during the year to plan and to hear
reports. We maintained
an active role in
community fund-raising
for cancer research
witn a rnspiay at tne
Wisconsin Breast Cancer
I$i
S I thu
Showhouse. Oza Holmes
and Joan Sagan initiated
plans for a Susan G.
Komen Race for the Cure
in Milwaukee for 1999. Seventy-five
percent of the funds raised from this
event remains locally for prolects in
our community. Cancer prevention
remained a priority. SSMC will be
the nucleus center in Milwaukee for
the second national breastcn
prevention trial, the STAR (study of
tamoxifen versus raloxifene) trial, with
Julie Jensen its coordinator. A goal
of 22,000 prticipants makes this
perhaps the largest prevention trial
1

1•
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ever to be attempted. Surgeons at
SSMC will be participating with other
surgeons across the country in clinical
trials research sponsored by the newly
formed American College of Surgeons
Oncology Group. Consideration was
given to establishing a resource room
at SSMC to further serve the needs of
cancer patients. A public education
plan was formulated for community
outreach to increase awareness of the
importance of cancer screening and the
treatment resources that are available.
We collaborated with the National
Cancer database by contributing data
on colorectal cancer and lymphoma to
the national pool.
This year’s annual
report concentrates on
colorectal cancer, the
fourth leading organ site
for cancer in the nation
and the third most
frequent cancer among
both men and women.
Colorectal cancer causes
56,600 deaths each year
in the USA and presents
a major challenge for
diagnosis and treatment.
_--fhe freqiiencyof colorectal cancer at
SSMC reflects thenational statistics.
Much information is becoming
available about the genetics of risk

1999
$

and progression of colorectal cancer. Attention to diet
and regular screening currently offer the most promising
avenues for reducing the morbidity from this particular
malignancy. We need to emphasize these strategies.
It was a pleasure to chair the cancer committee at SSMC
again this year. I wish to thank the dedicated members
of the cancer committee and all at our institution who
participate in the effort against cancer for their good works.

L..
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199$ was highlighted by tl
approval of the cancer prgram
at West Allis Memorial/lospital
at the highest level posible
granted by the C2nimission on
Cancer. In addifon, 1998 saw the
comp1etioñ of several studies and
thibeginning of new ones. The
West Allis former include colorectal cancer,
Memorial Hospital diagnosis and therapy thereof,
Chairman’s Report
and our data revealed that we
Maury B. Berger, MD
F.A.C.P. compared favorably with the
national benchmarks. It is obvious
from increased surveillance by the primary care physician
community, along with more aggressive endoscopy, that
these lesions are being found at an earlier stage. We also
began studies on prostate cancer
and early breast cancer. In regards
to breast cancer, a sub-committee
was formed to look at several
aspects of care which included
increased use of sentinel lymph
1
node mapping and radiation
therapy referrals for early lesions
when appropriate. We are still
below the national level of 70% of
all breast cancers having local
surgery and increased efforts will
be made so that our numbers in the future will
approach that.

home care and hospice branch which
has allowed many patients to stay at
home in their final days in comfort
with the assistance of this excellent
nursing staff. We saw a continuation
of our “Positive People” evening
support group, which is quite popular
and an increase in informational
service access for patients and their
families through Joan Crouse, the
librarian. I wish to thank Lisa
Robinson for her outstanding work in
overseeing the data development of all
the oncology programs for the Aurora
Regional System.

— —
— — — — —

::———1—

This past year saw the establishment of the regional Aurora
laboratory facility at West Allis Memorial Hospital with at
least six pathologists on campus at all times and laboratory
testing for hematology/oncology that I feel would rival any
university center. In regards to supportive care, the Aurora
Visiting Nursing Association has developed an excellent

U
U

—

This issue of the 199$ Cancer
Program update includes the new
regionalization as previously
mentioned of Sinai Samaritan,
St. Luke’s and WestAllis Memorial.
I feel this has ken very successful thus
far and we h’ve had very fruitful
quarterly meetings at the Heil Center
with representatives from these three
9

institutions and administrative staff for
the cancer and Vince Lombardi
program through Aurora Health.

Cancer Committee Membership
West Allis Memorial Hospital Cancer Committee Members
• Maury Berger, MD Chairman, Medical Oncology
• Linda Barrows, MD Physical Medicine & Rehab
-

-

I would also like to welcome William
Laffey, who has assumed the new
position of regional director for cancer
services for the Aurora system. I am
sure that with this emphasis on system
wide coordination of cancer services,
it will be beneficial to the patients and
the Aurora provider community.

• Kenneth Bastin, MD Radiation Oncology
-

• Brian Butler, MD Urology
• A. Craig Evans, MD Gynecological Oncology
• Donald Feinsilver, MD Psychiatry
-

-

-

• John Kelly, MD Otolaryngology
• John Hanson, MD Medical Oncology
-

-

• Ronald Hart, MD Medical Oncology
-

• Thomas Lass, MD Anesthesiology
• Steven Sperling, MD- Radiology
• Rodolfo Suaverdez, MD Family Practice
-

I feel strongly that West Allis
Memorial Hospital, through the
combination of its excellent
laboratory, radiation therapy,
diagnostic radiology, and physician
staffs, will continue to meet national
and community standards for
oncology care.

-

• Terence Roth, MD Surgery
• Shelly Underhill, MD Pathology
-

-

• Richard Kellar Administration
• Maria DeNario, MSN Social Services
-

-

Outpatient Nursing
• William Laffey, MBA Regional Director Cancer Services
• Becky Pogacar, RN, MSN Nursing
• Lisa Robinson, RHIA, CTR Data Registries
• Monique Swiecichowski, RN, BSN Research
• Pat Kadlec, RN

-

-

-

-

-

• Vicki Volp, RN, MSN, Quality Management
• Phil Whitton, RTT Radiation Oncology
-

-

St. Luke’s Medical Center Cancer Committee Members
• Jeffrey Derus, MD, Chairman, Urology
• Kenneth Bastin, MD Radiation Oncology
• William Deshur, MD Surgery
-

-

• Ajit Divgi, MD Medical Oncology L
• A. Craig Evans, MD Gynecologic Oncology
-

-

Gastroenterology
Medical Oncology

• Daniel Geenan, MD
• John Hanson, MD

-

-

• Ronald Hart, MD Medical Oncology
-

• Jeffrey Knajdl, MD Psychiatry
• Ann Lefever, Ph.D Immunotherapy
-

-

1999
10

N

cancer committee
membership

• Mahmood Mirhoseini, MD Cardiothoracic Surgery
• Gordon Mortensen, MD Ansthesiology
-

-

• David Munoz, MD

Family Practice

-

/

-

-

/

-

.

-

-

• Michael Nordstrom, MD Otolaryngology
//
• William Pao, MD Radiation Oncology
• Jorge Pellegrini, MD Pathology
o Elaine Thomas, MD Pediatrics

• Mitchell Pincus, MD
Radiation Oncology
• Gary Shapiro, MD
Medical Oncology
• Allen Torkelson, MD
Medical Oncology

-

• Len Wilk, FACHE Administration
-

-

• Patty Abella, RN
Regional Manager Oncology
-

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

JonaHIanTreiiaMD—Mdical Oncology
Mark Wenzel, MD Radiology
Vicki George, RN, Ph.D Regional Vice President
Patty Abella, RN Regional Manager Oncology
Sheri Hackbarth, RHIA Cancer Registry
Grace Jesson, MSW Social Services
William Laffey, MBA Regional Director Cancer Services
Pam Lyon, RN, OCN ABMT Coordinator
Rev. Marica Marino, M.DIV, B.C.C. Pastoral Care
Jennifer Martone, RN, MSN Inpatie CNS
Donna Metoff, RN, MSN Inpatient Nursing
Kristin Niendorf, MS, CGC Genetic Counseling
Sharon Paulson, RN SLSS Oncology
Lisa Robinson, RHIA, CTR Clinical Data Registries
Mary Runge, RN, MSN Visting Nurses Association
Donna Theesfeld, RN Quality Management
Carol Tutino, RN, CCRC Research
Kerry Twite, RN, OCN- CNS VLCC
Marija Weidman, RN, MSN- Business & Market Dev.
Phil Whitton, RTT Manager Radiation Oncology
Sol Yoder, PharmD Oncology Pharmacy
-

-

-

-

• Nancy Briggs, RN, OCN Research
-

• Jacque Coons, BS, RRT
Quality Management

-

• Cindy Ganzel, RN, RHIT
Clinical Data Registry

-

-

-

-

-

-

-

-

-

• Barb Haag-Heitman, RN
Women’s Health
• Oza Holmes, RN, OCN
Breast Health Center

-

-

• Julie Jensen, MSN, RN, NP Nursing
-

• William Laffey, MBA Regional
Director Cancer Services
-

• Margaret Lange, RN
Outpatient Oncology

-

-

-

• Janet Lotegeluaki, RN, OCN CNS
• Pam Maier, RN Inpatient Nursing
-

-

-

-

-

-

Sinai Samaritan Medical Center Cancer Committee Members
• William Donegan, MD Chairman, Surgery
• Betty Amuzu, MD OB/GYN
-

-

• Mary Mavraganis, MSW
Social Services

-

• Kristin Niendorf, MS, CGC
Genetics Counseling
• Lisa Robinson, RHIA, CTR
Clinical Data Registries
• Mary Runge, RN, MSN
VNA Hospice Services

-

-

-

• Phil Whitton, RTT
Radiation Oncology

-

• Sol Yoder, PharmD
Oncology Pharmapy
-

• Mark Gennis, MD Internal Medicine
• Robert Hall, MD Pathology
• MargeryHoward, MD Med. Oncology
-

-

-

• Howard Johnson, MD Radiology
• Thomas Kinney, MD Plastic Surgery
• Scott Levin, DDS Oral Surgery
-

-

-
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lorectal cancer
experience and excellence
Pathologic/Histologic Tumor

Grading and Staging

/

Dr. C. Dukes publisl a
pathologic study of one thousand
cases of rectal carcinoma in 1940
This artjcihas become the
-—stañdard upon which subsequent
Pathological Overview pathologic staging has been based.
Colorectal Carcinoma Dr. Dukes expanded upon the
W G. Doos, MD clinical observation that
a digitally
Pathologist,
ACL examined rectal carcinoma that
is freely moveable has a good
post-operative survival, while one that is fixed and
immobile has a poor postoperative survival. Examining
the histology of these resected specimens, he clearly
identified that carcinoma limited to the mucosa or
submucosa corresponded to a freely moveable tumor while
that which invaded the muscularis propria, became fixed
and eventually immobile. He further showed that regional
lymph node metastases offered an even poorer prognosis.
His original stages have been referred to as “Dukes’ Stage
A, B or C”. This basic terminology and its corresponding
relationship to survival statistics has withstood 60 years of
time. Numerous revisions of the original Dukes’ categories
have been published. However, all corroborated his original
observation, mainly that the deeper the tumor invades
the worse the prognosis and that the presence of lymph
node metastases at any depth of invasion confers the
poorest prognosis.
I

/

With the advent of the TNM Staging and grading of
malignancies, it has been decided to essentially incorporate
and/or expand upon Dr. Dukes’ original observations. The
pT category refers to the depth of tumor invasion in a
resected specimen, pN refers to the number of regional
lymph node metastases, and the pM refers to the presence

or absence of distant metastases. What
is important to note is that the pT
category of this system does not refer
to the size of the tumor, as is the case
for virtually all other malignancies.
Extensive investigations have not
shown any clear-cut relationship of
colorectal tumor size to that of
prognosis. There is an important
corollary here that frequently escapes
the medical community, namely that
a small carcinoma can be just as
devastating as a large one.
Histologic grading of colorectal
carcinomas according to the TNM
classification suggests that four
categories (Grade I through Grade 4)
be used in reporting data to cancer
registries and tumor boards.
Unfortunately, most institutions prefer
to use the time honored three-grade
system of well, moderately or poorly
differentiated adenocarcinoma.
Although the overwhelming majority
of carcinomas of the colon and rectum
are adenocarcinomas, there are a small
percentage of variants, which have a
poor prognosis, notably signet-ring
carcinomas, small cell carcinomas
and undifferentiated carcintthtfit
have no evidence pfany type of
differentiation, The presence or
absence extensive amounts mucin
production (so called colloid
carcinomas) also appear to have a

/
/

worse prognosis, however, some
published reports have made the
opposite observations.
Additional pathologic prognostic
parameters have been identified and
have been proposed as important
features to include in a pathology
report. The proximity of the leading
edge of a carcinoma to the radial
resected margins, the presence or
absence of direct serosal involvement
by tumor and extramural venous
invasion. The time honored tradition
of dividing the regional mesenteric
lymph nodes into those that are
proximal to, at the level of, or distal to
the carcinoma is less frequently used.
However, it continues to be a
suggested standard approach in
many pathology textbooks, as in
the proximity of lymph nodes to the
transected mesenteric vascular pedicle.
The category of pTis refers to
carcinoma in-situ. Histologically this
combines several entities that have at
one time or another had different
terms. The presence of severely
dysplastic cells within colonic glands
that are still bounded by the glandular
biiehtmebrane without any
evidence of invasion has in the past
been referred to as severe or high
grade dysplasia. The previous

1999
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designation of carcinoma in-situ involved a spectrum of
severely dysplastic cells within colonic glands to those
glands that form cribriform patterns but still without any
definite evidence of invasion. Once invasion had been
identified beyond the gland into the mucosa, this previously
was referred to as intramucosal carcinoma. All of these
above entities have a minuscule (approaching 0%) capacity
to metastasize and therefore have been collectively referred
to as carcinoma in-situ that is either intraepithelial
or intramucosal.
Colorectal Premalignant Lesions

It is important to differentiate risk factors from
predisposing conditions and from premalignant lesions.
A risk factor is defined as conditions that are associated
with a higher incidence than expected of carcinoma in a
cohort population. Risk factors might include; age,
gender, family history, diet, geography or unusual
environmental conditions.
A predisposing condition is a process or disease condition
that has a known associated increased risk of developing
carcinoma in a given cohort. Examples of this would
include chronic ulcerative colitis, schistosomiasis, previous
history of either adenoma, or carcinoma, Crohn’s disease
and potentially previous exposure to radiation.
A premalignant lesion on the other hand is a recognized
morphologic entity that has the potential to become
malignant. In the colon, the currently recognized
histopathologic gold standard is dysplasia, or increasing
degrees of cytologic atypia of cells lining the colorectal
glands. The majority of the time dysplasia is present within
well-recognized exophytic type adenomas, which
traditionally are divided into tubular, villotubular and
villous. There is an increasing awareness of an uncommon

lorectal cancer
experience and excellence
type of adenoma, which is flat and perhaps slightly /
ulcerated and which was originally recognized in iividuals
with hereditary non-polyposis colonic carcinom,/The
third category o dysplasia is one in w ic t epe is no
gross visible abnormality and the dysplasticells are
microscopically identified in random co1nic biopsies
typically in surveillance biopsiesfm patients with
longstandeoniactiviilcerative colitis.
Recognizing and diagnosing varying degrees of dysplasia in
exophytic or flat adenomas is not difficult and traditionally
shows high concordance rates in interobserver correlations.
This is not true, however, in de novo dysplasias, which
occur in chronic active ulcerative colitis. The difficulty is
due to the active mucosal inflammation that is associated
with glandular and cellular destruction and very brisk and
exuberant cellular regeneration and hyperplasia. These
latter features are very difficult to differentiate from true
dysplasia. Published interobserver concordance rates have
ranged anywhere from 60% to 80%. An attempt to
standardize criteria for grading dysplasia in the colon under
these conditions was attempted by a panel of internationally
recognized gastrointestinal pathologists in the early 1980’s.
The original classification was complex and included highgrade, low-grade, indefinite (probably dysplastic, indefinite,
probably reactive) and negative for dysplasia. Over the
ensuing 16 years, the indefinite subcategories have been
dropped. There is currently an attempt to reevaluate criteria
for dysplasia by an international committee.
Malignant Polyps
The term “polyp” is a gross visual description of any lump
or bump or exophytic lesion projecting from the surface of
the colorectal mucosa. The majority of these, in fact, are
not true tumors (adenomas) and can be sub-categorized as
mucosal folds, hyperplastic polyps, lymphoid aggregates,

inflammatory polyps, etc. A small
percentage of colorectal polyps
(approximately 10%) represent true
glandular neoplasms or adenomas.
By histologic definition these represent
colorectal glands that contain variable
degrees of dysplastic cells and create
a small mass or projection from
the surface.
The term “malignant polyp” has
created some confusion. This due in
great part to the fact that many terms
have been modified or dropped in the
terminology of colorectal adenomas.
The original consensus terminology
differentiated high-grade dysplasia
from carcinoma in situ from
intramucosal carcinoma in-situ from
intramucosal carcinoma. However
since the colonic mucosa is essentially
devoid of lymphatics, the metastatic
potential of all these lesions is
essentially zero. For this reason, there
is an increasing consensus opinion
to refer to these lesions as in situ
carcinoma corresponding to the pTis
designation of the TNM classification.
By extension, invasive carcinoma is
now being defined as that which has
metastatic potential at the time of
diagnosis. This has bemdëfied
anatomically as the muscularis mucosa
above which there are only rare
lymphatic channels. The current
definition then of invasive carcinoma
is based on identifying carcinoma that
15

/1
is invading into or through the
muscularis mucosa, into the
submucosa. Anything above that
is in-situ.

-

The overall incidence of in-situ
carcinoma in adenomas has been
recorded to occur somewhere between
8% and 13% while that of invasive
carcinoma somewhere between 2%
and 6%. The term “malignant polyp”
now has to be either redefined or
sub-categorized. If only in-situ
adenocarcinoma is identified with any
polypectomy specimen, no further
treatment is typically warranted
providing the lesion has been
adequately excised. If on the other
hand an invasive adenocarcinoma is
identified in a polypectomy specimen,
specific histologic criteria must be
looked for and evaluated in order to
predict either recurrence or metastasis
at the time of diagnosis. Specifically,
the deepest point of penetration of the
carcinoma should be clearly stated
(polyp head, neck, stalk, etc) and
its proximity to the polypectomy
resection margin. Also, the histologic
grade of differentiation and the
presence or absence lymphatic or
vascu1avasion. An increasing
number of investigators are now
agreeing that a polypectomy specimen
with an invasive adenocarcinoma that

1999
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is within 1mm to 2mm of the margin, or has poorly
differentiated carcinoma, or has lymphangio invasion
should be considered for further definitive treatment.
A pathologist’s role in examining and dissecting
polypectomy specimens is quite important. It becomes
critical for the pathologist to identify the stalk (frequently
retracted into the head after fixation) or the base of an
otherwise flat or bulky adenoma.
The base or transected stalk should be identified, clearly
designated (e.g., India ink), and the specimen transected in
such a way that an appropriate cross-section be placed on
a slide for definitive microscopic examination. With this
kind of an approach, it is usually possible to identify the
relationship of any invasive carcinoma to the anatomic
landmarks of the adenoma and to the margin of resection.
Clearly large polyps that have been fragmented become
increasingly more difficult to examine and evaluate and not
uncommonly the resection margin is unclear.

lorectal cancer
experience and excellence
According to the 1999 Facts and Figures Report by the Ame/ican Cancer Society, men are more likely to develop
colorectal cancer than women with a rate of 54.5 per 100,00 for men and 38.2 per 100,000 among women (see SEER
numbers). But study findings by the NCDB (98 Rectal St%ly and 96 Colon Study) and findings in the Metro Region of
Aurora Health Care show that women were diagnose4ore than men by a margin of at least 4%.
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Subsite distribution of colorectal tumors was compiled from the Metro Region Hospitals with comparative data excluding
the rectosigmoid junction. Therefore, the NCDB’s rectal percentage is probably higher due to the inclusion of rectosigmoid
junction cases. The findings show that the majority of colon tumors are found in the right colon.

Substitute Distribution of Colorectal Cases
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To compare stage of disease at diagnosis to the nation general summary staging was used. The benchmarking outcome
shows more patients at our metro region hospitals were diagnosed with regional disease by 10% than the nation, but also
reveals the metro region had fewer patients diagnosed with stage IV disease than the nation.

General Summary Stage at Diagnosis
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Most Frequent Histology: The most frequent occurring histology for colorectal cancer is adenocarcinoma at 67%. 14%
includes mucin varients and the rest include adenocarcinomas found in villous, tubuovillous and adenomatous polyps.
There are no comparative statistics available at this time.

Histology

Percent of Cases

Adenocarcinoma/Adenoma

67

Mucinous Adenocarcinoma/Adenoma

7

Mucin Producing Adenocarcinoma

7

Carcinoma In Situ

4

Carcinoma NOS

2

—Adenocarcinoma in Tubulovillous Adenoma
Adenocarcinoma in a Villous Adenoma

4

Adenocarcinoma in Polyp

2

Other Histologic Types

3
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lorectal cancer
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Colon cancer screening ha/ only
recently received the attei4ion it
truly deserves. With the/help of
well recognized celebyiies, the
I
mass media has r4ided a wealth
of informati9n4egarding the
preva1nof colon cancer and
steps can be taken to identify
Screening Using fecal tumors at a curable stage.

F,

-4

Occult Blood Testing

Thomas Puetz MD In tne Umtea
Statea tnere are
approximately 130,000 new cases of colon cancer
diagnosed yearly with 50,000 deaths. This makes colon
cancer the second most common cause of death from a
malignancy surpassed only by lung cancer. The difference
from lung cancer, however, is that colon cancer deaths
can be prevented in a majority of cases if screening
recommendations are followed. The prevention of deaths
occurs as a result of identifying malignant tumors in an
early stage and by removing their precursors, adenomatious
polyps. Ten-year survival rates for early stage cancers
are greater than 90% compared to less than 10% for
metastatic disease.
1

1

1

Understanding the difference between screening, surveillance
and diagnostic testing is crucial when reviewing guidelines
for colon cancer screening. The definition of screening
involves the application of a detection method on an
asymptomatic patient. Included are: fecal occult blood
testing (FOBT), flexible sigmoidoscopy, colonoscopy and
barium enema (BE). Surveillance is the term used for testing
patients who have a personal history of colonic neoplasia
or inflammatory bowel disease, but otherwise remain
asymptomatic. The usual test for surveillance is a
colonoscopy. Diagnostic exams are used to identify a
source of symptoms or lab abnormality. Examples would
include iron deficiency anemia or hematochezia.

Screening guidelines for colon cancer
are available from a number of
different sources including the
American Cancer Society, Agency
for Healthcare Policy and Research
(AHCPR), and the U. S. Preventative
Task Force. The guidelines endorsed
by the ACS and AHCPR are nearly
identical with regards to screening the
asymptomatic patient. The only
difference is the AHCPR includes
isolated FOBT as a screening option.
The ACS technique for FOBT is
outlined below.
• Take 2 smears from 2 sites of 3
separate bowel movements
• Develop within 7 days
no rehydration

-

Avoid for 48-72 hours prior
to testing the following that could
cause false positive or false negative
results respectivly.
False Positive Results
Red Meat (beets, lamb,
processed meats)
Uncooked Turnips, Broccoli
and Radishes
NSAID and ASA

>

325 mg/day

False Negative Results
Cantaloup/and Other Melons
(waterm/lon excluded)
VitamØi C Supplements>
500 ng/day
19
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Primary care providers need to know
the strengths and weaknesses involved
with each of the recommended testing
strategies. FOBT is the only test,
which has been shown to decrease
colon cancer mortality rates through
the use of randomized control trials.
The decrease ranged from 15% in the
European studies to 35% in the United

States. The fairly large difference noted between these
studies likely occurred from rehydration of the stool
samples in the United States. This led to a higher false +
rate with more colonoscopies being performed.
Recommendations for FOBT should include the following:
with any positive test, a complete evaluation of the colon
needs to be performed. Repeating a FOBT for confirmation
is not an option as poiyps and malignant lesions can
bleed intermittently.

When looking at family, personal and previous medical history of patients diagnosed in the Metro Region, two statistically
significant findings are noted. The first is that 14% of the patients had a family history of colorectal cancer and secondly,
an interesting 29% of the female population has had a previous total abdominal hysterectomy or bilateral
salpingoopherectomy (TAWBSO). Also of note, is 9% of the patients had a prior history of polyps.

History
Family History of Colorectal Cancer

Percent
14%

Personal History of Colorectal Cancer

A
-r
io

Multiple Primaries.. .Colon, Rectum

o 0/io

Previous TAH/BSO

0/

I-

29%

(calculated on female population only)
Previous History of Polyps
Personal History of Cancer

00/
/0

-,

Breast 5%
Cervix 1%
—

—

Lung

—

1%

Ovary—2%

Prostate 4%
Uterus 2%
—

—

Other—7%
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According to the incidence and mortality report from the Arierican Cancer Society, the risk of developing colorectal
cancer increases with age in men and women. The incidenqé is reportedly 6 times higher among persons ages 65 years
and older than among persons aged 40-64, with 75% of1atll new cases being diagnosed after the age of 65. In comparing
our statistics to the rate of cancer reported nationally b the NCDB. Sinai Samaritan Medical Center’s population was
diagnosed at an earlier age. This may be correlatedt6 the African American population, who the nation also reports as
having a higher incidence and mortality rate than men and women of the other racial and ethnic groups

Age at Diagnosis of Colorectal Cancer
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0
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symptoms
Of the reasons leading to diagnosis of colorectal carcinoma within the Metro Region, patients presenting with
Familial
were the leading precursor to diagnosis (78%). Screening for colorectal cancer diagnosed 17% of the cases.
reasons.
history accounted for 2% of the diagnoses and 3% were diagnosed due to other or unknown

Reason Leading to Diagnosis

familial history
-,

other
symptoms

0/

3 /0

78%

4.
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Evidence exists that reductn in
colorectal cancer morbidiy and
mortality can be achieved through
detection and treatmii of early
stage colorectal caners and
identification and removal of
adenomat6iis poiyps, the precursors
ofo1orectal cancer. Current
Screening Using American Cancer Society screening
Flexible Sigmoidoscopy recommendations for colorectal
Daniel J. Geenen, MD
cancer include digital rectal
examination every year for ages 40 and over, annual fecal
occult blood tests for age 50 and over. Recent studies have
shown that only 17.3% of people greater than 50 have had
fecal occult blood testing. Additionally, of people greater than
50 only 9% have had a flexible sigmoidoscopy.
There are two major reasons to screen asymptomatic
individuals for colorectal cancer. The first is to diminish
mortality from this cancer through early detection and
possibly through secondary prevention. The second reason is
to select a limited number of patients who are to be examined
by colonoscopy. Universal colonoscopy for screening is
considered too expensive, and therefore, is reserved for those
most likely to have positive findings on previous screening
methods or who are under surveillance. Reduction in
colorectal cancer mortality and possible reduction in incidence
through detection and removal of adenomas are very
important benefits of screening. Flexible sigmoidoscopy to
60 cm can decrease mortality risk from colon cancer 60-80%.
Individuals who undergo colonoscopy because of a false
positive screen probably do not need to be screened for a
decade. Detection of early stage colorectal cancer also may
involve less post surgical care such as adjuvant therapy
including chemotherapy and radiation. A cancer detected
early has a five-year survival rate of 90%. Metastatic colon

cancer has a five-year survival of
10%. Complications of flexible
sigmoidoscopy are rare; it is a cheap,
quick, effective and safe screening test.
Presently, the one major limitation to
the benefits of colorectal screening is
the low compliance rate outside of
study populations. The sigmoid
examination covers the distal 60cm
of the colorectum. The coverage is
adequate because greater than 50% of
colorectal cancers occurs in the distal
colorectum and a substantial number of
individuals with cancer or adenomas
proximal to the splenic flexure have
neoplasms distal to the splenic flexure
as well. For these individuals total
colonoscopy would follow
sigmoidoscopy and the proximal
lesions discovered.
Certain groups of people are to be
screened and subjected to closer
surveillance with colonoscopy. They
include people with a history of
colorectal cancer, polyps, ulcerative
colitis or a family member with
colorectal cancer. The risk of developing
colon cancer in this population is
significantly higher, and therefore, more
intensive surveillance is necessary. It is
important as a medical community fci
us to push forward these screening
techniques for colon cancer, as we can
significantly decrease morbidity and
mortality of colon cancer.

23

diagnosis,
The malority of the Metro Region patients had a relatively short duration of symptoms prior to presenting for
usually one to two months. The five most common symptoms patients presented with were rectal bleeding, occult
in more
positive stool, abdominal pain, anemia and change in bowel habits. In this figure, patients may be included
than one category.

Colorectal Cancer Symptoms at Presentation

rectal bleeding
abdominal pain
anemia
occult positive stool
change in bowel habits
malaise
V

bowel obstruction
pelvic pain
ER visit for obstruction
jaundice
I

10%

0

I

20%

Percent of Patients

1999
24

/

30%

40%

:Elorectal cancer
experience and excellence

)

New advances in the diagn/sis
and treatment of colon aiid
rectal cancers have resiF(ed in
improved survival rates and
lifestyles for patiepf. Specifically,
advances in surgical techniques,
oncology- radiation therapy
hãre been responsible for
Surgical Management these improvements.
James V Kias, MD
Endorectal ultrasound has improved staging of colorectal
cancers. In the case of rectal cancers, endorectal ultrasound
has led to the identification of early cancers. These are
amenable to less morbid (transanal excision) procedure
and result in equivalent survival and recurrence rates as
more radical procedures. Endorectal ultrasound has not
been as helpful in the colon secondary to its inaccessibility.
The surgical management of colon cancers has changed very
little in the last few decades. The tumor and its draining
lymphatics are resected with a margin of normal colon.
The remaining ends of the bowel are then reconnected using
either staples or sutures. Laparoscopic bowel resections
have gained partial acceptance because they minimize
incisions, pain, and length of hospital stay and time out of
work. Unfortunately, these goals are frequently not achieved
for many reasons. Furthermore, there is significant concern
about increased recurrences in patients with stage I and
stage II cancers treated laparoscopically as compared to
“open” procedures. This has significantly hindered the
widespread use of laparoscopic techniques in the
management of colorectal cancers.
The availability of intraoperative radiation therapy (IORT)
has facilitated the ability of the surgeon to tackle locally
invasive lesions of the retroperitoneum, flank and pelvis
that would not have been possible years ago. This has

resulted in improved local control of
cancers, improved quality of life for
patients, and even improved survival
for some.
Many more technical advances have
occurred in the surgical treatment of
rectal cancers than colon cancers.
These advances have developed from
the desire to avoid colostomies thus
preserving “normal” gastrointestinal
function. Permanent colostomies
(abdominal perineal resections or
APR) have become exceedingly rare.
Transanal circular staplers have
allowed the surgeon to reconnect the
bowel in situations that would have
otherwise required an APR.
Techniques such as extended low
anterior resections, coloanal
anastomosis, and transanal excisions
(so called sphincter-saving procedures)
have nearly replaced the APR. This
has all been accomplished without
compromising recurrence and survival
rates. In addition, morbidity and
mortality have been reduced with
these less invasive procedures.
The addition of preoperative
chemoradiation therapy has resulted
in the increased use of these phinciei—
saving procedures.”-Preoperative
chemoradiationitherapy in rectal
cancers has resulted in downstaging,
improved resectability, reduced
recurrence’rates and improved survival.
25

It has been recently recognized that
surgeons with specialty training in
surgery of the rectum have better
results with regard to local recurrence.
Surgeons using specialized techniques
such as Total Mesorectal Excision
have demonstrated markedly reduced
local recurrence rates. This technique
involves the meticulous removal
of the rectum and its mesentery in
specifically described planes to
prevent contamination of the pelvis
with cancer cells.
Metastatic colorectal cancer to the
liver has been traditionally dealt with
by surgical extirpation. Hepatic
cryotherapy has added a therapeutic
modality for the treatment of those
tumors previously not amenable to
surgical therapy. The two modalities
may be used in conlunction with each
other. Furthermore, cryotherapy
accomplishes similar survival and
recurrence rates as excision with less
morbidity and mortality. Cryotherapy
uses a probe placed in the tumor with
the liver using ultrasound guidance.
The probe is cooled with liquid
nitrogen, cooling the tumor to -191
degrees Celsius creating an “iceball”
hichrroy the tumor cells.
Radioimmunoguided surgery or
R.I.G.S. uses radioisotope labeled anti-
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bodies to intraoperatively find tumor cells not detectable by
standard surgical techniques. Most often used for patients
with recurrent colorectal cancei radiolabeled antibodies are
injected into the patient 48 hours prior to surgery. During
surgery, the surgeon uses a probe that detects the isotope
that has attached itself to the tumor. Once identified by the
probe, the tumor is removed. The specificity and sensitivity
of this modality have limited its widespread use.
Recently, more attention is being paid to the patients’
functional outcomes rather than more traditional
parameters of morbidity, mortality, survival and recurrence.
Functional outcomes refer to patients’ continence, number
of bowel movements, sexual function, and overall well
being. New surgical techniques have followed to improve
these measures in addition to the more traditional
parameters. The use of a specially designed “J” pouch made
from the remaining colon has improved patient function
post-operatively by reducing the number of movements and
increasing bowel control. This has been especially important
when patients are receiving postoperative chemoradiation
therapy, which may further compromise function.
Trends for the future focus on less radical surgery with
improved multimodality (surgery, cheotherapy, and
radiation) treatments. In addition, trials are underway
looking at lymphnode mapping, already used in breast
cancer to better delineate the most appropriate patients
for adjuvant therapy. Ultimately, the treatment and or
prevention of colorectal cancers is in the hands of the
molecular biologist through gene therapy.

rectal cancer
experience and excellence
Surgical resection alone of the primary tumor was done in t majority of the cases (65%) at all of the facilities, followed
by surgery and chemotherapy (20%). Radiation was used a,s either primary or adjuvant treatment 11% of the time and no
treatment was given in 3% of the cases.
/
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The ACoS study looked at the type of anastomosis that was done with surgical resection. Of the cases utilizing
anastomosis, 46% used the staple method, 23% of them were hand sewn, 28% did not have an anastomosis
and 3% were unknown.

Method of Anastomosis
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28%

2 0/
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Enterostomal Therapy
Mary Sue Coffey,
RN, CETN

Enterostomal Therapy
Jan Avakian-Kopatich,
RN, CETN
Enterostomal Therapy (ET) is a nursing specialty which
focuses on the care of patients with diversions of the
intestinal or urinary tracts (i.e. colostomies, ileostomies,
urostomies) and chronic wounds. The Enterostomal therapy
nurses are key to those ostomy patients who may have or
have had surgery for colorectal cancer, bladder cancer,
diverticulitis, ulcerative colitis, Crohn’s disease and fistulas
to name a few. The ET nurses work in close collaboration
with general surgeons, colorectal surgeons and urologists
in preparing patients for either a temporary or
lifetime diversion.
A patient may first encounter an ET nurse pre-operatively
where they explain the surgical procedure, characteristics
of the stoma opening, appliances/appliance management
techniques, skin care, diet and where to obtain ostomy
supplies post-discharge. During the pre-op visit the ET
nurse selects a site on the patient’s abdomen for the stoma
opening, considering the type of ostomy, abdominal
contoui skin folds, beitline, and style of dress. This is a
crucial step in preparing one for ostomy surgery, as a well
positioned stoma allows for secure adherence of an
appliance. Appliance security is key to a patient achieving
confidence in the ostomy so that a normal lifestyle
can be resumed.

During hospitalization the ET nurse
educates the patient and significant
others in appliance management and
skin care. This is often an emotional
time for patients as they encounter
their new stomas. However, by
discharge they are usually able to
empty the appliance themselves and
have a good beginning understanding
of the appliance change procedure.
A visiting nurse, or visiting ET nurse
follows the patient in the home
setting until independence in ostomy
care is achieved.
ET nurses find their roles to be
extremely rewarding as they help
patients adjust to their ostomies
physically and emotionally. “Taking a
patient from a very overwhelmed and
sometimes hopeless state of mind to
a realization that life can go on as
before, makes it all worthwhile,”
states Jan Avakian-Kopatich, RN,
CETN. “Patients truly appreciate
our expertise and the time we spend
teaching them how to care for
themselves. Ostomy care deals with
a very personal bodily function. The
patient ha to feel comfortable with
the nurse caring for it. Once he or she
does, a close personal rapport ofren
develops and the ET nurse becomes
a key contact person for as long as
the patient has the ostomy. It is what
nursing is all about for me.”
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The metro region of Aurora Health
Care employs seven ET nurses. They
are Jan Avakian-Kopatich (SLMC),
Judy Bell (SLMC), Mary Sue Coffey
(WAMH and SLSS), Margaret Driss
(St. Luke’s Wound Care Center),
Jeanne Linnemanstons (VNA),
Barbara Provo (SSMC), and
Kay Wienke (VNA).

Based on NCDB’s 1996 report on colon cancer, all ethnic groups have generally similar stages of disease at presentation,
except for African Americans who have a slightly higher incidence of late stage disease. According to the 1999 Facts and
Figures, African Americans have higher colorectal cancer incidence than men and women of other racial and ethnic groups.
Comparison of new cancer cases by race among Metro facilities show Sinai Samaritan with the highest number of African
Americans, which may correlate to the finding of patients diagnosed at a younger age at that facility.

Race by Hospital at Diagnosis
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Although cancer of the coln is
very treatable, it is still tI3é second
most common cause of,cancer
death in the United ,tàtes.
Approximately thrë-quarters of
patients present with localized
disease,_aii.d resection for cure is
--pösible. Unfortunately, one third
The Role of these patients will eventually
of Chemotherapy
develop recurrent cancer. Thus,
in the Treatment
over half of all colon cancer
of Colon Cancer
Gary R. Shapiro, MD patients will ultimately die from
distant metastases. In addition
to palliative treatment for metastatic colon cancer,
chemotherapeutic strategies have developed to prevent
postoperative relapses.
Adjuvant Therapy
Adjuvant therapy refers to the administration of
chemotherapy (or radiation therapy or both) after curative
surgery to eradicate micrometastases that are responsible
for postoperative relapses. The goal of this therapy is cure.
Recurrence following surgery is clearly related to the degree
of penetration of the cancer through the bowel wall and
the presence or absence of tumor in the loco-regional
lymph nodes. Large prospective randomized trials have
conclusively shown that patients with loco-regional lymph
node involvement (Stage III or Dukes’ C) benefit from
systemic adjuvant chemotherapy employing 5-fluorouracil
based chemotherapy regimens. With very mild toxicity,
adjuvant chemotherapy reduces the recurrence rate by 40%,
and the death rate by 33%.

metastases. With its limited
penetration into the bowel wall,
stage I (Dukes’ A) colon cancer is
curable by surgery alone. Although
25 30% of patients with Stage II
(Dukes’ B2, B3) disease will
eventually succumb to their illness,
the adjuvant studies have only shown
a trend favoring adjuvant therapy in
this group of lymph node negative
patients. Adjuvant therapy cannot be
recommended routinely in this group,
but, pending further studies, most
oncologists do treat the subgroup of
high risk Stage II patients who have
colonic obstruction or perforation.
-

In recent years, 6 months of
postoperative 5-fluorouracil and
leucovorin has become the standard
approach for patients with stage III
adenocarcinoma of the colon. Twelve
months of 5-fluorouracil and
levamisole may also be considered,
but at least one trial has shown this to
be inferior to the 5-fluorouracil and
leucovorin regimen. Eligible patients
should be considered for entry into
clinical trials comparing various
postoperative chemotherapy regimens,
postoperative radiation therapy,
biological therapy, or combiitionsdF
these modalities.

There is no consistent evidence that adjuvant chemotherapy
is beneficial in the absence of loco-regional lymph node

/‘•
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Advanced Disease
For many years, 5-fluorouracil has
been the mainstay of chemotherapy for
the treatment of patients with
metastatic (Stage IV, Dukes’ D) colon
cancer. Response rates in these patients
range from 10 50%. Combination
chemotherapy has not been shown to
be more effective than 5-fluorouracil
alone. A recent Eastern Cooperative
Oncology Group study showed
complete responses in 0.5%, partial
responses in 14%, and disease
stabilization in 7.6% of patients with
metastatic colon cancer regardless of
how 5-fluorouracil was combined with
leucovorin, PALA, or interferon. The
median duration of response in the
group treated with 5-fluorouracil
alone was 8 1/2months. 5-fluorouracil
chemotherapy has also been used
as a radiation sensitizer, and
intraarterially to treat liver metastases.

advanced disease. In addition, many other exciting new
agents, including other topoisomerase I inhibitors
(Hycamptin), thymidylate synthase inhibitors (Rahitrexed,
Tomudex), platinum analogues (oxaliplatin), and
oral fluorinated pyrimidines (Capecitabine, oral
5-fluorouracil, eniluracil) are undergoing preclinical
and clinical investigation,

-

Over the past few years, the
topoisomerase I inhibitor, irinotecan
has emerged as the first effective drug
for patients whose tumors no longer
respond to 5-fluorouracil, It produces
response rates of 15 30% in this
group.itis now the standard
treatment for patients with refractory
colon cancer, and it is being tested in
various combinations in all phases of
-
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Despite the promise of these new agents, the treatment of
advanced colon cancer remains palliative. Recent progress
in understanding the molecular biology of colon cancer may
ultimately permit the identification of those patients most
likely to benefit from adjuvant and palliative treatments.
Such advances may also identify alternative targets for
chemotherapy, and improve prognosis in this disease.
Clinical research trials are available throughout the
Aurora System. It is of the utmost importance that patients
with colon cancer be given the opportunity to participate
in these studies.

/1

figure 2

Figure 1
Isodose distribution for a rectal cancer using a
posterior field weighted 0.5 and opposed lateral
fields with 45” wedges and weighed 0.25 each. As
in the bladder tumor, hot spots are present under
the thin portion of the wedges.

The addition of an anterior field reduces the hot
spots in the lateral aspect of the pelvis. The posterior
field is weighted 0.5, the lateral fields 0.2 each, and
the anterior 0.1.

figure 3 and 4
A and B. Typical treatment fields for preoperative irradiation of rectal cancer. Small bowel contrast given prior to
the simulation procedure is helpful for field shaping. Rectal contrast is inserted prior to simulation of the lateral
fields. If a boost is given, a small volume of air can be inserted in the bladder. The air will rise and indicate the
posterior aspect of the bladder in the prone patient, which is helpful when the lateral fields are designed.
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Large bowel cancers are suJdivided
into colon adenocarcinorns and
rectal adenocarcinomas,%nd the
treatment regimens fo/both
differ markedly. Byiefinition, the
rectum beginaf’the point where
the large-bwel loses its mesentery.
—Athe lymphatic drainage patterns
are different, cancers above and
below the peritoneal reflection are
managed differently. Likewise,
presenting symptoms vary as rectal
y present with melena, and colon cancers
t with abdominal pain.
the initial treatment of choice for colorectal
en surgical resection. Important prognostic
rmining who would benefit from adjuvant
include tumor penetration of the bowel
jrapynode involvement, as both factors are
[th a high rate of local recurrence. Other poor
ctors include deletions from chromosome
Iovexessi0n of p53, aneuploidy, and high

using local radiation therapy in the adjuvant
rmined by the patterns of failure following
kirative surgery. Radiation therapy is an
Li treatment modality, but it is typically
in clinical situations where the risk of local
high enough to justify its use and when an
can be delivered safely.
cancer, the role of adjuvant radiation therapy
pers is not well defined. The most common site
surgery is abdominal rather than pelvic.
ailure does not result

in the same degree of morbidity as
inpatients with rectal cancer who
develop a local pelvic recurrence.
There are subsets of patients with
high local failure rates, and a few
retrospective series suggest an
improvement in local control and
disease free survival with the use of
postoperative radiation therapy, either
to the tumor bed or whole abdomen,
particularly in patients with 14, NO,
MO or T4, N1-2, MO disease.
However, preliminary data from an
intergroup trial showed no significant
improved outcome with adjuvant
radiation, 5FU, and levamisole over
5FU and levamasole alone (INT 0130,
ASCO, 1999). Thus, the use of
radiation therapy in colon cancer
remains under investigation.
In contrast, radiation therapy has
clear benefits in a number of cohorts
of patients with rectal cancer. In
resectable rectal cancer, it has been used
historically in both a postoperative
setting as well as a preoperative setting.
A number of series have shown that the
risk of local recurrence in surgically
managed patients without adjuvant
therapy in stages Ti 2, NO, MO i less
than 10%. However, it increased to
15-35% in stages 13, NO, MO and Ti,
Ni, MO and A5-65% in 13-4, Ni-2,
MO adenoc4rcinomas.
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A number of randomized trials and
retrospective series have shown an
improvement in local control with
adjuvant postoperative radiation
therapy, versus a surgical control arm
(16% vs. 25%, p=O.06). More
impressive results have been seen in
combined adjuvant postoperative
radiation therapy and chemotherapy
in-patients with 13-4 and node
positive rectal cancers. There are three
randomized trials of postoperative
combined modality therapy and
they have consistently shown an
improvement in overall survival,
disease free survival, and local control.
Radiation therapy has also been used
in a preoperative setting. This has
both biological and physical
advantages as, theoretically, there is
increased radiosensitivity due to more
oxygenated cells, and there is no post
surgical small bowel fixation in the
pelvis. Furthermore, preoperative
therapy results in significant
downsizing of the tumor allowing
for sphincter preservation in 75-80%
of patients who otherwise would
need abdominoperineal resection.
Siiiillarfy;preoperative therapy may
improve the resectability rate,
particularly in patients with locally
advanced or unresectable disease.
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Other novel approaches in such patients include integrating
intraoperative radiation therapy (IORT), whereby one
can use either electrons or brachytherapy to deliver
additional radiation to the tumor bed or region with the
highest risk of local failure.
Radiation therapy is typically delivered via a 3 or 4 field
shrinking field technique to 5040 5400 Cgy. (Figure 1&2).
The sacral canal and regional lymphatics, including the
internal iliac and prescaral lymph nodes are typically
included in the pelvic fields. After an abdominoperineal
resection, one usually includes the perineum with the
radiation ports to reduce the risk of perineal recurrence,
which can range up to 20-25%. (Figures 3&4)
-

There are many questions that have yet to be answered,
and there appears to be an emerging trend towards local
excision alone and integrating adjuvant therapy in the
appropriate candidate. Currently, the focus of the Radiation
Therapy Oncology Group (RTOG) is to examine issues of
radiation dose, fractionation, and the incorporation of new
radiosensitizers into the treatment schema.
Clearly, radiation therapy and systemic chemotherapy have
proven to be integral additions to surgery in the treatment
of colorectal adenocarcinomas.

lorectal cancer
experience and excellence
Colorectal cancer is a maiyr cause
of death from cancer in Western
civilizations; it will c1aih
approximately 55,00cI lives in
the United States iii 1999. The
age-adjusted Aeath rates are
highly yatible in populations
‘t&ited in different parts of the
Chemopreventative world. For example, there are 3.4
factors cases per 100,000 in Nigeria
Maury B. Berger, MD,
FA. C.P. compared with 35.8 cases per
100,000 in Connecticut per year.
This obviously indicates that there are environmental,
dietary, as well as genetic components, which makes
population studies often difficult but must be taken into
light in doing preventative studies.

4

We know that early detection by fecal occult blood testing
and flexible sigmoidoscopy may decrease the risk of
colorectal cancer by 20% to 30%; however, most of the
United States population does not undergo appropriate
screening. Therefore, epidemiologists have focused on
understanding a molecular basis for the chemoprotective
facts resulting from drugs, foods, and other materials to
decrease the incidence of this cancer. Substances explored
as chemopreventive agents in colorectal cancer include:
1. The nonsteroidal anti-inflammatory drugs (NSAIDS)
which may inhibit the evolution of formation of adenomas
by their inhibition of cyclooxygenases and decrease of
prosticlinosynthesis; 2. Antioxidants, such as vitamin
E or C which may modulate carcinogenic substances; and
3. Folate and calcium, which may interfere with tumor
growth and replication. Dietary intervention, such as
decreasing fat intake and increasing fiber consumption
have been linked to a lower incidence of colon cancer in
many epidemiologic studies. This field is continuing to
evolve and some data are difficult to analyze. This article

attempts to summarize some of this
data on dietary and pharmacologic
approaches to the prevention of
colorectal cancer.
Cyclooxygenases
Studies in humans have evaluated the
effect of aspirin and NSAIDS on the
relative risk of colorectal cancer. The
most common drug used, has of
course, been aspirin and in the use of
ASA and the NSAID there has been
little information regarding the most
effective dose and duration of drug
use, which is extremely important
since one would have to take these
drugs long term as a preventative
measure. The cyclooxygenases
inhibitors have been studied in a
variety of settings including the
Nurses Health Study in which a
protective effect was seen after several
years of aspirin use. Similar studies
have revealed a protective effect of
NSAIDS in relation to adenomatous
polyp detection. Some groups have
found that continuous NSAID use
results in a 40% to 50% reduction in
relative risk for colorectal cancer.
The mechanisms for chemopreveution
of these drugs is not entIrely clear but
is thought by rsearchers that the
inhibition of cyclooxygenases
enzymes affcts the conversion of a
rhodanic acid to prosticlanins and
other eicsanoids. The two inducible
37

isoforms of cyclooxygenases COX- I
and COX-2 both affect prostiglandin
production and may work as
mitogens or tumor promoters in a
wide variety of cell types.
Disregulation of COX-2 coincides
with development of gastrointestinal
malignancies. Increased COX-2
expression has been detected in
8 0-90% of colorectal
adenocarcinomas and in 40-50%
of premalignant adenomas. This
elevation of COX-2 expression may
be secondary to other events such as
the APC gene (adenomatous polyposis
coil), K-ras mutation and P 53
mutation. Thus, the new class of
NSAIDS that are highly selective for
the inhibition of COX-2 enzyme but
lack inhibition of COX- I may prove
to be very helpful in inhibiting
tumor growth.
NSAID$
Other studies have shown that
NSAIDS induce apoptosis (orderly
cell death) and alter expression of cell
cycle regulatory genes. Many studies
are underway using NSAID like drugs
for the prevention of gastrointestinal
malignaicies as well as skin, lung,
prostate and breast. Recent trials
show that NSAIDS combined with
statin drugs such as mevacor may
work to prevent colon dysplasia that
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can lead to cancer. This has been an exciting area and
future studies will show this safety and efficacy as a
pharmacologic agent in the future.
Other Drugs
Other drugs that may affect cancer-developing pathways
that are under study include:
Arachidonic acid in fecal matter are cytotoxic to
the colorectal epithelium and may promote
cell transformation.
Alpha-difluoromethylornithine (DFMO) may inhibit
cellular proliferation and suppress carcinogen inducing
oncogenes such as p2l, ras expression. Retinoids seem to
reduce proliferation, induce differentiation and perhaps
inhibit basement membrane invasion angiogenesis and
have been used for a number of years in a variety of
chemoprevention studies.

Oltipraz
Oltipraz is a synthetic compound similar to those found
in cruciferous vegetables. This compound may affect
regulation of certain metabolic enzymes to prevent their
carcinogenic properties and has
been shown to have
antineoplastic activity in several
target organs such as bladdei
skin, mammary gland and lungs.
Calcium

Theorists have thought that
calcium may act by binding fatty
and bile acids. The high fat
western diet (100 to 150 grams
per day of fat) produces

)
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hyperproliferative changes in the colonic mucosa o/
humans and rodents. An increased calcium conceration
may also directly inhibit the development of ma’ignancy
by inhibiting the proliferation of pluri potent tem cells in
the colonic crypt epithelium. However, atplesent, the role
of calcium in colon carcinoma prevention is unclear
Dartmouth College has an ongQmg study of using calcium
per day with every three
year colonoscopy.
fat
Dietary factors have thought to be an important cause of
colon cancer and may account for as much as 90% of the
variation in rates of this tumor in different parts of the
world. Recently 13 epidemiological studies were evaluated
and found that in 12 of them, increased fat intake resulted
in an increased incidence of colorectal cancer. However,
the results of epidemiological studies are suggestive but do
not conclusively define an association between dietary fat
and colon cancer. There are several mechanisms that have
been proposed to explain how fat intake might increase
the risk for colorectal cancer. One study has suggested that
fatty and bile acids cause irritation
of the colonic epithelium leading to
an increase in the rate of cellular
proliferation. Another mechanism
involves the role of fat in colon
carcinogenesis because of an
interaction among fat, bile acids
and bacteria. At the present time,
the NCI is conducting the Polyp
Prevention Trial One in which
patients are on a low fat, high fiber,
high fruit and vegetable diet and
monitoring for the incidence of
bowel adenomas.

fiber
Epidemiologists in the 70’s found that
colon cancer was rare in Africans
whose diets are high in unrefined
foods and contain more fiber than
those of westernized populations.
(Recent studies reveal little effect of
diet in general in the prevention
of colon cancer in the general
population.) Mechanisms for dietary
fiber to have an anticarcinogenic
effect have been proposed, including
binding of bile acids in the gut and
diluting the effects of potential dietary
carcinogens by increasing stool bulk.
Also, it is thought that fiber may
act as a substrate for bacterial
fermentation causing more short
chain fatty acid production which
are less carcinogenic. Several large
studies are going on at the present
time which should further define
fibers role.
Vitamins
The antioxident vitamins including
Vitamins E, C, and betacarotine
have been studied for their role in
preventicn’of cancers in humans. It
is thought that betacarotine can trap
organic free radicals andtôr
deactivate excited oxygen molecules.
Betacarotine also may prevent
genetic changes by preventing DNA
damage irduced by free radicals.
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Vitamin E functions as a free
radical scavenger to prevent lipid
perioxydation of polyunsaturated
fatty acids. Vitamin C may also act as
a free radical scavenger. Studies thus
far, however, have not shown a
significant decrease in colon cancer
risk with the above mentioned
vitamins. Several studies have shown
a reduction in colon polyps but there
is nothing conclusive and, thus, there
is no support for the use in colon
cancer prevention.
Folate
Researchers use data from the food
frequency questionnaires of 88,000
women who have participated in the
Nurse Health Study from 1980 to
1984. Women who had had a folate
intake of greater than 400 mcg. per
day in 1980 were less likely to be
diagnosed than women who had an
intake of less than 200 mcg. per day.
Women who had taken supplements
for 15 years or more showed a
significant decrease in colon cancer
risk (relative risk of 0.25). One theory
has reviewed the role of folate in
DNA methylation stating that an
_inadecluQte folate intake could lead to
abnormalities in DNA methylation
and thus to normal cell development.
A recent study following 29,000 male
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smokers in Finland suggested that a diet high in Folate
combined with low alcohol, high protein diet may have a
protective effect against colon cancer and further studies
are being done on the use of folate as chemopreventive of
colorectal cancer.
In summary,
it is thought
that the use
of NSAIDS
or aspirin,
and that a
diet low in
fat and high
in fiber, as
well as
regular
exercise, would be the best choice. Recent
recommendations for the prevention of cancer by the
World Cancer Research Fund include:
• Choose predominantly plant-based diets rich in a variety
of vegetable and fruits, legume and minimally processed
starchy staple foods.
• Avoid being underweight or overweight and limit weight
gain during adulthood to less than 11 pounds.
• Maintain physical activity.
• Eat 15 oz. to 30 oz. of five or more portions per day of
a variety of vegetables and fruits year round.
Limit consumption of fatty foods, particularly those of
animal origin to less than 25% to 30% of total calories
and saturated fat to less than 10% of total calories.

lorectal cancer
experience and excellence
•

Limit consumption of salted foods and the use o,)ble
salt in cooking. Use herbs and spices to season

t

• Do not smoke or chew tobacco.

/

As OUf knowledge base increases at the basic science level,
such as cellular promoters and inhibitors, oncogenes and
their over and under exwesslon, and other molecular
biological pathways,
I feel strongly that
more knowledge will
be gained and we will
come closer to a
regular regimen of
chemo prevention to
reduce the significant
incidence of colorectal
cancer in the
U
United States.
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Reqciich Trials for Colorectal Cancer
What will find the cure for cancer? Research. Res rch is
/
one of the most important elements in finding a/éure
for
this deadly disease. With so many treatment ‘odalities that
aim to prevent, treat and cure cancer, resafch is the factor
ihat helps determine which method &ics best. The Cancer
Program in Aurora Health care’s Metro Region is actively
pursuing that end bjr taking an active role in educating and
enrolling our patients in approved national studies. No
other hospital system in Southeastern Wisconsin can offer
its providers a brochure with over 250 open protocols for
their prospective patients. The GI protocols are listed in this
report. The entire listing of open protocols is updated on a
quarterly basis and distributed to all the staff physicians of
the metro region.

Some of the studies included on this brochure are
highlighted below with updates and highlights from 1998,
including studies that pertain to this year’s in-depth site
of disease, colorectal carcinoma.
CALGB

The Cancer and Leukemia Group B studies continue to be a
part of the clinical research program at St. Luke’s Medical
Center with 13 studies currently open. The studies cover
S different cancer sites, including breast, colorectal,
leukemia, lymphoma and respiratory.
In 1998, 13 patients were entered into CALGB studies. Four
of the 13 studies focus on colorectal cancer. They include:
CALGB 949$: SFU/Leucovorin vs. 5FU continuous infusion
+ Levamisole for Dukes B2 with obstructi
on or perforation
or resected Duke’s C 1-2.
CALGB 9581: Monoclonal Antibody 17-lA vs. observa
tion for resected Stage II colon cancer.

CALGB 9770: High dose vs. regular
dose Octreotide Acetate vs. Loperamide
for 5 FU induced diarrhea.

CALGB $9804: CPT-11!5FU/
Leucovorin vs. SFU!Leucovorin for
advanced adenocarcinoma of the colon
and rectum. This study was just recently
opened for patient accrual after the
chemotherapy agent Oxaliplatin (Oxal)
was added to the study.
Follow-up continues for approximately
175 patients in numerous CALGB
studies that either remain open for
additional accrual or are now closed.
For more information, contact Dr.
Ronald Hart (Elizabeth Meyer, RN,
Coordinator) at 384-5111 or Dr. John
Hanson (Carol Tutino, RN, CCRC,
Coordinator) at 385-3086.
Eastern Cooperative Oncology Group
(ECOG)
The Medical Oncology Clinic at
Sinai Samaritan Medical Center
is an affiliate of the University of
Wisconsin’s Comprehensive Cancer
Center (UWCCC) and the Eastern
Cooperative Oncology Group
(ECOG). In addition, the Ehnic is a
charter member of the Wisconsin
Oncology Network (WON), a newly
developed statewide network of
UWCCC affiliated hospitals and
clinics. Through this network,
43
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Wisconsin’s cancer patients have
greater access to innovative
investigational cancer treatments.
These include agents that have just
come out of the laboratory and are
being evaluated in humans for the first
time. One of these agents is perillyl
alcohol, a plant derivative, which is
taken orally.
Active ECOG studies include
evaluation of 5-FU (bolus vs.
continuous infusion) for colon cancer;
5-FU (bolus vs. continuous infusion)
with pelvic radiation for rectal
cancer; oral 5-FU and GW 776
(an enzyme inhibitor) for
metastatic colon cancer; and
monoclonal antibody 17 1A vs.
observation for resected Stage II
colon cancer.
—

Upcoming research projects in 1999
include studies evaluating additional
oral chemotherapy agents, including
the ECOG Phase III trial evaluating
oral 5-FU/ Eniluaracil vs. protracted
intravenous infusional 5-FU in
previously untreated advanced
colorectal cancer (E 5296).

Radiation Therapy Oncology Group IRTOGI

St. Luke’s Medical Center (SLMC) has been a member of
RTOG as an affiliate of Dartmouth Hitchcock Medical
Center since 1993. West Allis Memorial Hospital (WAMH)
was granted “joint center” status with St. Luke’s Medical
Center in 1998.
In 1998, on behalf of Principal Investigator Dr. Mitchell
Pincus, MD, 11 protocols were submitted and approved
for use by the Institutional Review Board (IRB). This
brought the total to 25 available RTOG protocols. As is
the philosophy of RTOG, these included studies have a
variety of focuses:
Adjuvant treatment protocols
were made available to patients
with node positive prostate
cancei poor-risk stage III
non-small cell lung carcinoma,
recurrent head and neck cancer,
resected pancreatic carcinoma,
PSA failure following radical
prostatectomy of the
prostate and high risk
endometrial carcinoma.
Quality of life and palliation
(using different treatment
schedules) is being studied on breast and prostate cancer
patients with painful bone metastases.
1

Fbföeinformation contact
Dr. Gary Shapiro, Principal
Investigator (Nancy Briggs, RN, MSN,
OCN, Coordinator) at’219-6591.
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An attempt to alleviate radiation induced toxicities is the
focus in two studies involving breast and head and neck
cancer patients. These studies evaluate the effectiveness of
various topical products in minimizing radiation induced
skin toxicity and the efficacy of prophylactic Salagen during
radiation to reduce xerostomia and mucositis.
-
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A new evaluation tool was put in place to measure and
record late effects of radiation treatment given to p,Itient
receiving therapy for head and neck cancer. And finally,
prevention was the focus of a study evaluating;lbw-dose
13-Cis Retinoic Acid (Accutane) in the preyeition of second
primary tumors in patients with Stage -Or II squamous cell
carcinoma of the head and neck
NSABP
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) began recruitment efforts for the second breast
cancer prevention trial in May of 1999.
The study of Tamoxifene and Raloxifene (STAR) will
compare proven benefits of Tamoxifen against Raloxifene in
22,000 post menopausal women 35 years of age and older
who are at increased risk of developing breast cancer.
The STAR Study opened in July 1999 at Sinai Samaritan.
Sinai Samaritan Medical Center is the Milwaukee
headquarters for the study and coordinates recruitment
efforts with participating institutions in Southeastern
Wisconsin and Green Bay. Dr. William Donegan is the
principal investigator for the study.
Sinai Samaritan Medical Center also participated in the
National Surgical Adjuvant Breast Cancer Prevention Trial
(BCPT) which was the first national trial using Tamoxifen
in women at high risk for developing breast cancer. The
study demonstrated that Tamoxifen reduced the incidence
of breast cancer in 13,388 high risk women, and Tamoxifen
was approved for this purpose by the Federal Drug
Administration in 1998. Sinai Samaritan was the
Milwaukee Headquarters for the study, 85 women in
Southeastern Wisconsin participated.

Autoloious Bone Marrow
Transplant ProQram

Opened in 1990, the Autologous Bone
Marrow Transplant (ABMT) Program,
under the direction of Robert Taylor,
MD, celebrated its 9th anniversary this
fall. The annual celebration reunites
patients, physicians, and other ABMT
Program staff members. Over 300
patients have been treated for cancer
with ABMT.
Research continues in the arena of
advanced cancers. The physicians and
scientists of the ABMT Program have
designed two state-of-the-art research
studies that combine ABMT with
immunotherapy. The first of these
studies involved patients with
non-Hodgkin’s lymphoma, Hodgkin’s
disease and multiple myeloma patients
and has just been completed. The
second study is still in progress and
involves women with metastatic breast
cancer. Though it is too early to draw
conclusions, the patients treated
thus far are without any significant
toxicities from the addition of
the immunotherpy.
Two non-experimental treatment plans
have been added to theABMT
Program this year. These treatment
plans are for patients with ovarian and
testicular cacer. The patients treated
thus far ha4re tolerated the therapy
very well.!
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In a continued effort to manage the
continuum of care in an efficient and
cost-effective manner, the ABMT
Program utilizes patient pathways.
These pathways outline the care
delivered at any time during the
ABMT process by all members of the
multidisciplinary team. Variations
from the standard are recorded and
analyzed as the cause and the
outcome. Performance
improvement measures are
then designed to address the
variances where needed.
Breast Care Program

-

Last year over 32,500
mammograms were performed at
over 25 sites in the Metro Region
of Aurora. Our aggressive and
widespread mammography
screening program increases the
identification of breast cancer in
its earliest stages. There was also
substantial growth in the number of
minimally invasive breast biopsy
procedures performed in Aurora’s
Breast Centers. Additionally, several
new treatment and diagnostic
procedures were advanced during the
earJjie investigational protocol
involving sentinel node biopsy, aimed at
obtaining prognostic information in a
less invasive way and thereby reducing
the morbidity associated with axially
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dissection, is near completion. A lymphedema and exercise
program for women who have had breast surgery, has both a
prevention focus and symptom management component.
Also new is the multidisciplinary care conference for newly
diagnosed patients with breast cancer at St. Luke’s Medical
Center. Participants in the treatment planning process
include surgeons, radiologists, pathologists, medical
oncologists, radiation oncologists, plastic surgeons, a
psychiatrist, pharmacists, nurses,
and mammogram technologists.
The conference is designed to
assist the patient’s treating
physician by offering a
comprehensive collaborative
treatment recommendation.
Enabling patients to participate
more in the decision making about
their care and treatment has been
another focus. A new customized
patient education binder, which
tailors and organizes information
specific to each patient’s case, has been developed and will
soon be available to all breast cancer patients in the Metro
area through the Breast Care Coordinators at St. Luke’s
Medical Center, Sinai Samaritan Medical Center, West Allis
Memorial Hospital and VLCC Slinger.
—

Cancer Counseling Center
Under the medical direction of Jeffrey Knajdl, M.D.,
and with nursing coordination provided by Barbara
Clinkenbeard, RN, MSN, N1 the Cancer Counseling
Center’s mission is to identify and treat psychosocial distress
in cancer patients. This is born out of the recognition and
understanding that by decreasing levels of distress, patients
may experience a host of benefits including a higher quality
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of life, better nausea and pain control, relief from
depression and anxiety, improved relationships, an,çI even
prolongation of one’s life. The psycho-oncology pfogram at
St. Luke’s has been carefully tailored and desigr(d under
the working models of programs at Memoiai SloanKettering Cancer Center and the Johns Hopkins Psycho
oncology program. It is a progranJll no other in the state
of

/

The Cancer Counseling Center also places a special focus on
the role of the cancer patient’s family and other significant
persons present in their lives. Every attempt is made to
maximize patients’ abilities to interact and communicate
with the critical people making up their support system.
The Cancer Counseling Center has as one of its goals to
screen every patient diagnosed with cancer for psychosocial
distress and to provide ongoing measures of quality of life.
This data will be collected on an ongoing basis so as to
allow the Center to be a hub of psycho-oncology research
worthy of national and international publication. The
National Comprehensive Cancer Network has published a
set of guidelines by which psychosocial distress in cancer
patients should be managed. The Cancer Counseling Center
embraces the approach, which includes integration of
psychiatric, psychological, social, and spiritual services.
Every patient seen undergoes a thorough psychosocial
evaluation and a determination of the treatment plan is
made based on that information. In fact, the Cancer
Counseling Center will be the central support system as the
plan to screen every Vince Lombardi Cancer Clinic patient
for bio-psycho-social distress comes to fruition by January
2000. Treatment options for those with moderate-high
distress include: (1) providing access to support groups,
(2) facilitating a referral for counseling or psychotherapy
(individual, family, or group), (3) starting medication

management, or (4) building a
combination of these three modes
of intervention, which is what most
often occurs.

Community Outreach
This activity continues to evolve in a
manner and at a pace now set by the
communities which we serve. As past
activities were examined it was

determined that on occasion the same
participants were attending every event
offered. While this is a dedicated
audience which should not be taken
for granted, the goal of this activity
has been and will remain reaching
those individuals who continue to have
no knowledge of prevention and early
detection. To this end it has become
increasingly more advantageous to let
our communities indicate the outreach
activities which are most appropriate.
So instead of “lectures” held at the
medical centers there are “brown-bag
conferences” held in the cafeterias of
local businesses at their invitation.
Instead of going to school for “career
day”, a class may come to one of the
Vince Lombardi Cancer Clinics for a
tour, information about health care
vocations, and being andtaying well
through life.
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Gynecologic Oncology

Immunotherapy Program

The Metro region of Aurora Health
Care extended its scope of services in
gynecologic oncology this year with
the addition of Anthony C. Evans,
M.D., Ph.D. and Jeannette Wade,
R.N., N.P. Dr. Evans is a fellowshiptrained (Duke University) gynecologic
oncologist whose practice is limited to
care of women with gynecologic
cancers and pre-malignant conditions.
Ms. Wade has expertise as a nurse
practitioner in the highly specialized
field of gynecologic oncology.

In the last year, the Immunotherapy Program was reviewed
by our Scientific Advisory Board, which consists of
nationally known physician researchers from the National
Cancer Institute and the University of Pittsburgh Cancer
Center. Each member of this board has expertise to evaluate
the areas our program is pursuing in order to provide
innovative, effective forms of immunotherapy to our
patients through the Vince Lombardi Cancer Clinics.
Dr. John P. Hanson, Dr. Jonathan Treisman and the other
senior investigators of our program presented written and
oral summaries of the progress of our work as well as our
future directions. The program received an excellent
reaction from this board which determined that we were
successfully proceeding towards bringing critically needed
therapies to our patients which would incorporate the latest
scientific and technical expertise available.

Comprehensive, state-of-the-art care
for women with ovarian, cervical,
uterine, vulvar, and gestational
trophoblastic tumors is available at the
Vince Lombardi Clinics and St. Luke’s
Medical Center. Dr. Evans also is
available to lend his expertise to
the management of women with
gynecologic neoplasms at other sites as
well. Care of these women is enhanced
by the availability of medical and
radiation oncologists skilled in
treatment of gynecologic cancers. The
region also offers the availability of
the Cancer Counseling Center,
Hypethaic Medicine, Lymphedema,
Nutritional, and Social Services as well
as the Ovarian Cancer Support Group.
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The William Schuett Cellular Laboratory continues to
provide cellular immune products for many of our clinical
trials. This laboratory modifies the technical advances
developed in our research laboratories for use in the
treatment of patients under carefully prepared clinical
protocols. The generation and administration of these cells
is closely regulated for patient safety and to this end the
laboratory received accreditation from the American
Association of Blood Banks (AABB) which determined that
we met or exceeded all requirements. Only about 10
laboratories in the United States have the capability to
generate the types of immune cells that we use to treat
patients and we are one of four that have this AABB
accreditation for cellular production of immune therapies.
The Vince Lombardi Gene Therapy Laboratory has
continued to focus on developing genes which can instruct
cancer killing T cells how to find and efficiently kill cancer
cells. In the laboratory setting, these gene-educated T cells
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bind cancer cells more effectively, kill the tumor cell7’ more
efficiently and produce other immune products cap/ible of
killing surrounding tumor cells. The Gene Laborafory, in
conjunction with the clinical cell laboratory, is4ow in the
process of revising and refining procedures st that these
successful research activities can evolve nito patient
treatment In the coming year, we will be conducting testing
of the geieproduGt-whichii required by the FDA and
preparing quantities of this gene that we will require for
subsequent clinical trials to treat patients with colon, renal,
breast or lung cancer.
The Cellular Research Laboratory has been developing the
laboratory and clinical expertise to bring tumor vaccines
into our armament of cancer treatments. The vaccine
approach to cancer therapy is designed to enhance a
patient’s immune system so that it can then function
efficiently to destroy tumor cells. This form of therapy will
be specifically generated for each patient’s tumor.
Preliminary results of clinical trials in other centers suggest
the potential for this form of therapy and points to the
importance of our program pursuing this treatment strategy.
We are currently awaiting final approval of a vaccine trial
to be conducted in collaboration with the National Cancer
Institute for the treatment of metastatic melanoma.

fluid when lymph nodes and vessels
are blocked, removed, or damaged.
It is triggered by the removal or
radiation of lymph vessels or nodes
and may occur following surgery or
treatment of breast, cervical, prostate,
uterine, or colon cancer, as well as
post injury or other surgical
procedures. It also may be a primary
condition that is congenital. Both men
and women are at risk. The condition
may occur following a recent medical
condition or procedure, or many
years later.
Lymphedema causes tissues to become
swollen, thick, and painful and
increases the risk for infection leading
to more complicated medical
conditions. With proper evaluation
and intervention, lymphedema can
be treated and controlled allowing
a person to lead a positive and
productive life.
Pastoral Care

Lymphedema Program
On June 14, 1999, Aurora Rehabilitation Center announced
the opening of Lymphedema Services at the Vince Lombardi
Cancer Clinic at St. Luke’s. Lymphedema Services are also
being offered at West Allis Memorial Hospital and at
Aurora Rehabilitation Center Slinger, with new programs
opening this fall at Sinai Samaritan Medical Center and
Aurora Rehabilitation Center Waukesha.
—

—

Lymphedema is the chronic swelling of a body part, most
often an arm or leg, resulting from the accumulation of

The Pastoral Care Department offers
professional spiritual care to patients
and families who are dealing with
cancer. Chaplains provide daily visits to

inpatients and outpatients, co-fcilitatç
cancer support groups,provide
sacraments as requested, provide 24
hour coverage/for spiritual care needs,

and communicate with area clergy as
requested b’y patients.
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A highlight of the past year was the
development and sponsoring of the
first annual Retreat for Women with
Cancer. Chaplain Marcia Marino
(along with Kerry
Twite, CNS, Laura
Molleson, Breast
Program Assistant, and
Sharon Paulson, RN,
SLSS) developed an
\
overnight retreat
program which
I
included prayer,
meditation, journaling,
massage therapy, and
music therapy. The
retreat, which took
place at St. Francis
Retreat Center in Burlington, WI,
was well received by the participants.
-

Another highlight was the Fifth Annual
Cancer Residence for Clergy, Pastoral
Ministers, and Parish Nurses. Eight
participants had an opportunity to lie
on a Radiation Oncology treatment
table, study tumors in the lab, read
X-rays, tour the Vince Lombardi
Cancer Clinic, watch videos about
cancer evaluation and treatment, listen
to a patient panel discussion, and
nteractithphysicians, nurses,
psychologists, andother members
of the Cancer Services team.
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Multiple research studies have highlighted the importance
of spiritual care as a part of healing. Chaplains play an
important role on the clinical team providing spiritual
support for those who are dealing with cancer, their
families, and the staff who care for them.
Pharmacy
The Department of Pharmaceutical Services
within the Aurora Health Care Metro Region
strives to provide safe, reliable and specialized
care to our patients in collaboration with
other disciplines.
St. Luke’s Medical Center pharmacy
department is actively involved in supporting
healthcare professionals and patients with up
to date drug information. Pharmacists
participate in many multidisciplinary work
groups to facilitate meeting patient needs and optimizing
medication therapy.
The pharmacy department at St. Luke’s South Shore is now
located closer to the clinic to better serve our patients. There
is also a new outpatient pharmacy to provide additional,
convenient pharmacy services.
The pharmacists at Sinai Samaritan Medical Center
collaborate with nursing to assure delivery of treatments
to patients during non-clinic hours.
The pharmacists at West Allis Memorial Hospital, as well as the
other metro sites mentioned above, assess all oncology orders for
safety and appropriateness. This includes multiple checks that
are made to assure accuracy of preparation and administration.
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Based at St. Luke’s Medical Center, Aurora Health’ Care has
installed the first operational Gamma Knife in \7{sconsin,
and began treating patients in the fall of 199’ The Gamma
Knife is a state-of-the-art, high technology (ool dedicated to
performing radiosurgery of brain lesiofis. The Gamma Knife
is sOnarned because it houses-201 radioactive cobalt
sources with fFOi radiation beams converging on a
defined brain target. Subsequently, a highly intense
radiation dose is given to the brain target with minimal
dose to normal surrounding tissue. Typical Gamma Knife
applications include treating primary malignant, metastatic,
or benign brain tumors, arteriovenous malformations, and
such debilitating conditions such as trigeminal neuralgia.
Gamma Knife Radiosurgery precludes the need for open
brain surgery or hospitalization. Patients are treated
exclusively in the outpatient setting, with modest risk of
complications, and minimal discomfort. Gamma Knife
Radiosurgery requires the dedicated teamwork of
neurosurgeons, radiation oncologists, and medical physicists
for the selection, planning and treating of patients, and
affords definite advantages to linear accelerator
radiosurgery because small and complex shaped tumors
are more easily and more accurately treated in a cost
effective manner.
—

Social Service
The Social Service staff functions as an integral part of
a multidisciplinary oncology team and yet stands
independently in the provision of patient advocacy and
skills unique to the discipline itself. Oncology patients are
in a distinctive place as they contemplate issues of morbidity
and mortality while at the same time undergoing treatment
that impacts all aspects of their life and lifestyle. It is at
this critical point where a social worker is able to make a
connection and offer emotional support.

The social worker’s expertise in family
systems and community resource
mobilization provides patients and
families with a foundation and
understanding of the process of dis

charge planning and the continuum of
care. Through ongoing interaction, the
social worker builds rapport through
which to assist each individual and
tailor their services accordingly. The
focus of our needs assessment and
practice may include but is not limited
to: family dynamics, environment,
education/career, support system,
financial, transportation, spirituality,
sexuality, alcohol and drug history,
domestic violence, crisis intervention
and community based affiliations.
These categories are researched on
behalf of the patient. A plan is then
formulated consistent with their
own needs, level of care and most
importantly their personal desires
and preferences.
For those patients that face sensitive
issues around end of life planning, the
social worker addresses such uncertainty
with special attention to a patient/family
educational needs, hospice consideration
and a support system of agencies
cognizant of dying witi dig 1 The
oncology social worker then integrates
community agencies with Aurora-wide
resources to fbrmulate a discharge plan
that is persna11y unique to a patient’s
needs and ‘vishes.
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Among the different roles that a social
worker has, one that is most pivotal
is that of a liaison. Oncology social
workers ensure clear, concise
communication and the provision of
information by acting as a bridge
between the patient, family, internal
and external staff and services. This
empowers patients and families with
the necessary tools to take better
control of situations where they may
feel a need for guidance or direction.
Such empowerment is often
accomplished through education about
and execution of Advance Directives.
This is a specialty unique to the Social
Worker with no other discipline except
pastoral care authorized, under the
state statutes, to do so. The Durable
Medical Power of Attorney for Health
Care and Living Will provide patients
and families with legal tools in which
to specify wishes related to their
ongoing health care. The Durable
Power of Attorney document further
allows for a patient to designate a
spokesperson in the event of
incapacity. It also provides the
multidisciplinary team with
information about their individual
valueind belief systems and thus
ensures that the patient’s wishes are
carried out while under medical care.
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The Social Services department honors and actively
promotes highly individualized care and service to our
patients and their loved ones at a time when their needs
may be greatest and their resources weakest. With the
oncology social worker’s expertise and compassion, life’s
transitions can be made less of a hardship. The covenant
that is created places the patient and family at the center,
as equal members, in the decision making and treatment
process, respecting their wishes with regard to quality of
life and survival.
Patient Resource Centers
Patient education resources play a vital part in assisting
patients in participating in their treatment decisions with
their care providers. With this concept in mind, space is
allocated in the planning of each Vince Lombardi Cancer
Clinic site to accommodate a patient resource center. For
example, the patient resource center at the Vince Lombardi
Cancer Clinic in Slinger was
established and stocked with
the assistance of the local
medical facility auxiliary. In
the past few years patient
resource centers have been
established at the Vince
Lombardi Cancer Clinic
sites in Kenosha,
Manitowoc, St. Luke’s
South Shore, and Lakeland
Medical Center.
For many of these clinic
sites space is as big an issue
as support, and so each patient resource center is as unique
as each clinic site. But just as each clinic site achieves and
maintains the standards of the Vince Lombardi Cancer
Clinics, so too, do all patient resource centers meet a
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standard. All centers maintain a collection of patient
teaching materials regarding diagnosis by disease ses;
treatment options, side effects and anticipated oufcomes;
local support group listings; a CancerHeip computer; and
information on prevention and early detection. Many of
the centers also provide book and videofape collections
1ha4lition to a comfortable space-f6 go through these
materials alid-v+e-w*ideas.
Vince Lombardi Cancer Hoffine
The Vince Lombardi Cancer Hotline served as the “call-toaction” for a multi-media campaign promoting prevention
and early detection awareness from August 1998 and
through early spring of 1999. Beginning with four phone
banks held during the evening news on WTMJ Channel 4
and promoted in statewide newspaper advertisements and
through articles in Aurora Health Care publications as “The
Game Plan”, a cancer risk assessment questionnaire was
offered to callers. This tool can provide risk assessments for
nineteen primary cancer sites. Callers who completed their
risk assessment tool and returned it in the prepaid envelope
for evaluation received the results of their risk assessment
and follow-up materials that were customized to their
results. By serving as the registration point for callers who
wished to participate in this awareness activity, the Hotline
was able to provide additional information to callers who
had more needs or had already been diagnosed and were
looking for treatment options, second opinions and clinical
trial information.
-

The Hotline continues to serve the
local, statewide, national and now
international communities. With calls
received from Germany this past
year regarding participation in the
Autologous Bone Marrow
Transplantation Program by a
recurrent lymphoma patient the
Vince Lombardi Cancer Hotline has
broadened its service horizons. By use
of faxes and the Hotline it was
possible to cross an ocean and six
time zones in order to provide
an evaluation and treatment
recommendations to this caller.

Ntumor board repor/’
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Regional Tumor Board Report

A wealth of oncology information is
provided throughout the metro region
each week, through a forum called
Tumor Board. These open conferences
focus on prospective case review and
provide multidisciplinary discussion
for the entire spectrum of health care
providers. This informal consultation
among physicians provides viable
options for treatment of cancer
patients and subsequently enhances
their quality of care.
Physicians who attend tumor board
feel the conferences enhance their
knowledge and are grateful for the
opportunity to solicit recommendations
and interactive conversation from
colleagues outside their own specialty.
The routine attendance of tumor board
drastically reduces the need to make
lengthy consultative phone calls.
The format of the conferences includes
a brief clinical presentation, a summary
of diagnostic and pathological findings
and a description of any surgical or
therapeutic interventions. A
multidisciplinary discussion follows
withi commendations for further
therapy or sidy. This highly
informational and educational
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conference is recommended for all disciplines, including
medical students and residents. Other attendees include,
nurses, pharmacists, radiation technicians, cancer registrars,
social workers and other allied health professionals.
The Commission on Cancer mandates that approved cancer
programs in the “Comprehensive Community Hospital”
category meet weekly each year with a minimum of
47 total conferences annually. St. Luke’s Medical Center,
Sinai Samaritan Medical Center and West Allis Memorial
Hospital all fit into that category and currently meet weekly.
Hartford Memorial Hospital with a lower oncology caseload
needs to meet only monthly.
The generic tumor board covers an array of sites and types
of malignancies from week to week. There are dedicated
days and times of the week for the site-specific Breast
Conference (see times on facing page). Other services such
as pneumonology and otolaryngology have designated
weeks to present lung and head and neck cases. See the
complete listing of days, locations and times to attend
these conferences.

1

)

Tumor Boards

St. Luke’s Medical Center:
Tumor Board
Thursdays, 0730 0830
Stiemke Auditorium
—

)

cancer
conferences
Specially Boards
• Breast Conference
St. Luke’s Medical Center
Wednesdays, 0730 0900
Health Science Conference Room #3
—

• SIpaiSamaritan Medical Centef
Tumor Board
Fridays, 1200 1300,
Rapkin Auditorium

• Head & Neck Conference
St. Luke’s Medical Center
3rd Monday, 1200 1300
Health Science Conference Room #3

• West Allis Memorial Hospital:
Tumor Board
Fridays, 1200 1300,
Conference Room A/B

• GI Conference
St. Luke’s Medical Center
Tuesdays, 0700 0800
Health Science Conference Room #3

• Hartford Memorial Hospital:
Tumor Board
Monthly, Contact the
Dept. of Pathology for times.

• Endocrine Conference
St. Luke’s Medical Center
Tuesdays, 1200 1300
Health Science Conference Room #3

—

—

—

—

—

—

• Radiosurgery/Neurosurgery
St. Luke’s Medical Center
Tuesdays, 0730 0830
Radiation Oncology
Conference Room
—
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The Cancer Registry is an integral
component of the individual hospital
cancer program and an even more
important element for a networked
cancer program. In 199$, the Cancer
Registry of each individual hospital
became a regional section of the Metro
Clinical Information Services
Department, called the Regional Clinical
Data Registry. Twelve data registrars
collect data for a variety of services
but focus mainly on maintaining the
oncology patient database also known
as the Cancer Registry.
The Cancer Registry collects all
pertinent information on patients in
regards to their cancer diagnosis,
staging, treatment and follow-up.
This information is obtained from all
sources the patient may have utilized
for their care (in-house or out of
house). The type of information that
is collected includes patient
demographics, work-up, staging of
the disease, first course of treatment,
recurrence, subsequent treatment and
yearly follow-up for survival. All infor
mation is kept strictly confidential and
only aggregate information is released.

Ciirieñtly,each of our hospitals
maintains a separate database for
oncology data. Due to the
comprehensive and seamless

network of physicians and services
Aurora Health Care provides for its
patients, we find that patients more
than ever are overlapping between
facilities for their care. The
American College of Surgeons has
also come to this realization and
has recently released Network
Cancer Reaistrv ReDort
Accreditation Standards, to which
Lisa Robinson,
the Metro Region hopes to apply in
RHIA, CTR
the near future. In the meantime,
each hospital has been independently surveyed by the ACoS
and has achieved the highest level of accreditation available.
All new cancer cases are reported each year to the State of
Wisconsin and the National Cancer Data Base. The
standardization and mandated reporting of data to these
entities has enabled epidemiologists and researchers the
opportunity to benchmark this quality data and look for
trends and/or treatment breakthroughs based on what
regimens are reported for certain stages of disease.
In addition to collecting data on cancer patients and
following them for their lifetime, the registrars are also
responsible for conducting in-depth study reviews on
preselected sites. In 199$, St. Luke’s Medical Center and
Sinai Samaritan Medical Center participated in the
colorectal and lymphoma PCE study, while West Allis
Memorial completed the colorectal study alone.
4’

At SLMC, SSMC and WAMH a respective twenty two,
fifteen, and eight requests for data were made in 199$.
Quality control is maintained on 10% of the analytical
caseload and is reviewed by physicians for accuracy of
abstraction of diagnosis, treatment and staging. Other
quality improvement monitors that were spearheaded in
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1998 include the Aurora wide breast and cervical sc eening
initiative and at SLMC the DRG 410 project.
Continuing education events attended in 1998i4cluded the
Wisconsin Cancer Registrars Association Srl’ng Workshop
N hosted by our sister facility in Sheboygn’,’the 29th Annual
Natjonal Cancer Registrar’s Meeingln Boston, MA,
and th&3OthAnauaLS itheã em Wisconsin
Cancer Conference.
In October 1998, the clinical data registrars hosted the 23rd
Annual Wisconsin Cancer Registrars Association Meeting at
the Aurora Hell Conference Center. The meeting was a
tremendous success with rave reviews for our SLMC
physicians who spoke on the latest advances in their
respective fields. Thanks go out to the following physicians
for their time and effort in providing us with such current
knowledge and to the registrars, especially Sheri Hackbarth,
RHIA for organizing the event.
•
•
•
•
•
•
•
•
•
•
•

Kenneth T. Bastin, MD
James Bruckman, MD
Wilhelm G. Doos, MD
James V. Klas, MD
James L. Mahoney, MD
Mohammad I. Malik, MD
Michael R. Nordstrom, MD
William J. Pao, MD
Lawrence A. Sterkin, MD
Robert F. Taylor, MD
James E. Williams, MD

Regional Clinical Data Registrars
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Sharon J. Collison, RHIT
Sheila Davis
Christine A. Doege
Cynthia J. Ganzel, RN, RHIT
Sheril L. Hackbarth, RHIA
Jamie A. Keen
Mary B. Kissinger, RHIA, CTR
Yolanda D. Levy
Sharon A. Miller (retired)
Tracy L. Miller
Ramona Miranda
Karen L. Pollock
Marilyn Raciti
Patricia A. Recely, CTR (Reg. Assist)
Lisa A. Robinson, RHIA, CTR
Jane E. Seymour, RHIT, CTR

199$ data revie/
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2,790 new cancer cases were seen in the Metro Region in 1998. The number of new cancer cases has increased at all
the facilities from the previous year of 1997. Site numbers include St. Luke’s Medical Center 1,910 (include St. Luke’s

South Shore) with 84% classified as analytical (diagnosed and or treated within the first course of treatment), Sinai
Samaritan Medical Center, 321 with 90% analytical, and West Allis Memorial 480 with 94% analytical. For all other
graphs in this report St. Luke’s South Shore cases will be included in the SLMC numbers. Also note, that due to a lack of
formal registry at Hartford Memorial in 1998, specific statistics will not be included in other data summaries. Therefore,
for the remainder of the report the total number of cancer cases seen by the approved cancer programs equals 2,715.
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site distribution 1998
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Site Group

SLMC

SSMC

WAMH

TOTALS

Breast

325

94

80

499

Lung

275

39

72

386

204

10

43

257

207

35

65

307

75

9

47

129

62

12

17

91

59

22

90

76

9
7

10

93

152

16

11

179

Endometrium

44

6

17

Unknown Primary

38

6

8

67
52

Lip and Oral Cavity
Pancreas

17

3

4

24

51

13

5

69

Cervix

38

25

8

71

Esophagus

20

6

9

35
50
41

Prostate

—

Colorectal
Bladder/Ureter

-

Lymphoma
-Hmatopoetic
Kidney/Renal Pelvis
Skin

—

—

Stomach

39

8

3

Ovary and Unspec Sites

29

3

9

Brain, CNS, Nerves

39

1

43

Larynx

23

2

3
4

29

Liver

10

5

5

20

Thyroid/Endocrine

11

2

11

24

Testis

13

1

3

17

Soft Tissue
Gallbladder/Bile Ducts

22

1

4

27

11

0

5

16

Vagina/Vulva

11

5

3

19

Small Intestine

5

1

1

Thymus, Heart, Pleura

8

0

1

7
9

Bone

3

0

0

3

Eye/Adnexa

6

0

6

Retroperitoneum/Peritone

4

0

0
1

Nasal Cavity/Sinuses

15

1

16

Anus

4

0
2

2

8

Penis

1

0

0

1

Paratoid Gland
Tonsil/Hypopharynx

4

0

0

4

12

0

5

17

Other ill defined sites

Total

5

3

0

1

4

1914

321

480

2715
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region
In 1998, the number of new cancer cases increased at all metro region facilities from the previous year.
St. Luke’s Medical Center (1,914), Sinai Samaritan Medical Center (321) and West Allis Memorial Medical Center (480).

Cancer Caseload for Past 5 Years
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Review of all (2,715) new cases in 1998 shows the population served at St. Luke’s Medical Center and West Allis
Memorial Hospital is predominantly white with 97% and 99% respectively. By contrast the central city location of Sinai
Samaritan Medical Center serves a more diverse population with the majority being of African American (56%) descent.
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1998 data review
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The Metro Region hospitals had common top five sites with

Top 5
350

exception of SSMC, where cervix surpassed bladder.

Region Sites
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When comparing the top five sites in order of decreasing frequency in the Metro region to the incidence of cancer cases
reported by the state and the National Cancer Data Base (NCDB), it is noted that the Metro region sees a higher
percentage of breast cancer cases (19%), fewer prostate cases (9%) and a relatively equal number of lung (14%),
colorectal (12%) and bladder cases (5%).
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were women with 1,264 or
More women than men were seen at all Metro region sites in 1998. In total, 1,449 or 53%
in contrast more males
47% being male. The State of Wisconsin’s Cancer Incidence and Mortality Report for 1997, show
at 52% and females at 48%.

Gender 199$
70%

60%
52%

50%
0
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40%

40%
34%

30%
20%

10%
0

—
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• female

SLMC
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WAMH

STATE of WI

49%

34%

47%

52%

51%

66%

53%

48%

we find younger patients
When comparing age differences among the Metro Region Hospitals and the State of Wisconsin,
Center and West Allis
being diagnosed at Sinai Samaritan Medical Center with a mean age of 65. At St. Luke’s Medical
patients being diagnosed
Memorial the mean age is 75 with St. Luke’s Medical Center showing a larger portion of the
at ages slightly higher
diagnosed
younger than the mean, whereas at West Allis Memorial Hospital, the patients are being
than the mean.

Age at Diagnosis by Facility
40

35
30

15

v1o
0-29

40-49

30-39

50-59

60-69

age groups

1999
62

1

70-79

80-89

90+

•

SLMC

—

SSMC

•

WAHM

•

NCDB

re ional cancer committee
membership
Aur Health Care Metro Regional Cancer Committee M mbers
• Vicki George, RN, Ph.D
Vice President Metro Region
-

• William Laffey, MBA
Regional Director Cancer Services

• Jonathan Treisman, MD
Medical Oncology

-

• Patty Abella, RN
Regional Manager Oncology
-

-

• Maury Berger, MD -Chairman W%
Cncer Committee, Medical 9n1ogy

• Laura Burke, RN, Ph.D.
Regional Director
Nursing Research

• JeffrejDerusMD--Ci1ã1man
SLMC Cancer Committee, Urology

• Grace Jessen, MSW
Social Services Coordinator

• William Donegan, MD Chairman!
Liaison SSMC Cancer Committee, Surgery

• Rev. Raymond Korry, M.DIV, B.C.C.
Regional Director Pastoral Care

• Terence Roth, MD Liaison WAMH
Cancer Committee, Surgery

• Carolyn Maclver
Regional Director
Business and Market Development

//

-

-

• Robert Taylor, MD Liaison SLMC
Cancer Committee, Medical Oncology

-

-

-

-

• James Bruckman, MD
• William Pao, MD

-

Radiation Oncology

Radiation Oncology

-

• Lisa Robinson, RHIA, CTR
Regional Supervisor Clinical
Data Registries

-

• Mary Runge, RN, MSN
Director Visiting Nurses
Association Hospice Program
-

• Gary Shapiro, MD

Medical Oncology

-

• A. Craig Evans, MD
• Daniel Geenen, MD
• Jeffrey Knjadl, MD

OB GYN Surgical Oncology

-

Gastroenterology

-

Psychiatry

-

• Jorge Pellegrini, MD

Pathology

-

• Shelly Underhill, MD

-

• Reuben Eisenstein, MD

Pathology
-

Pathology

• John P. Hanson, MD Medical Oncology
-

• Donna Theesfeld, RN
Quality Management Coordinator
-

• Phil Whitton, RTT Regional
Manager Radiation Oncology
-

• Mary Kannenberg, RHIA
Director Quality Management
-

• Gloria Donais
Administrative Assistant
-

• Ronald Hart, MD Medical Oncology
-

• Mitchell Pincus, MD Radiation Oncology
-
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St. Luke’s Medical Center
Sinai Samaritan Medical Center
West Allis Memorial Hospital
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